Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 13/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8443733 | 0.83 | ROCK1 (0.37) | CYP3A4ROCK1PDPK1 | |
| SCHEMBL8442292 | 0.82 | ROCK1 (0.43) | CYP3A4ROCK1 | |
| SCHEMBL8443573 | 0.81 | HTR2C (0.46) | CYP3A4ROCK1 | |
| SCHEMBL13539068 | 0.80 | PDPK1 (0.39) | CYP3A4ROCK1PDPK1 | |
| SCHEMBL4404043 | 0.77 | SGK1 (0.53) | PDPK1ABL1 | |
| SCHEMBL1796868 | 0.75 | CAMKK2 (0.39) | CYP3A4ROCK1MAP4K1SCN9AABL1 | |
| SCHEMBL1798651 | 0.74 | MAPK8 (0.37) | CYP3A4ROCK1MAP4K1SCN9AABL1 | |
| SCHEMBL13505143 | 0.73 | ROCK1 (0.41) | CYP3A4ROCK1PDPK1 | |
| SCHEMBL13506721 | 0.70 | CYP3A4 (0.35) | CYP3A4MAP4K1ABL1 | |
| SCHEMBL15826669 | 0.68 | HTR1A (0.47) | CYP3A4PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1749829-B1 | JNK inhibitors | EISAI R&D MAN CO LTD (JP) | 2010-11-03 | — | — | EP | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-02-11 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-7645769-B2 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-12 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1749829-A1 | JNK inhibitors | Eisai London Research Laboratories Limited (GB) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035878-A1 | INHIBITORS OF C-JUN N-TERMINAL KINASES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS RELATING TO APOPTOSIS AND/OR INFLAMMATION | NFKBIA, CHUK, MAP3K1 | CYP3A4 4639/4885ROCK1 418/4885PDPK1 166/4885 |
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | NFKBIA, CHUK, MAP3K1 | CYP3A4 4639/4885ROCK1 418/4885PDPK1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.